首页 > 最新文献

Hormones-International Journal of Endocrinology and Metabolism最新文献

英文 中文
Sodium-glucose cotransporter-2 inhibitor-associated thrombocytopenia. 钠-葡萄糖共转运体-2 抑制剂相关血小板减少症。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-14 DOI: 10.1007/s42000-024-00614-2
Hironori Bando, Yushi Hirota, Wataru Ogawa
{"title":"Sodium-glucose cotransporter-2 inhibitor-associated thrombocytopenia.","authors":"Hironori Bando, Yushi Hirota, Wataru Ogawa","doi":"10.1007/s42000-024-00614-2","DOIUrl":"https://doi.org/10.1007/s42000-024-00614-2","url":null,"abstract":"","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PPARs: modulating lipotoxicity and thus inhibiting fibrosis. PPARs: 调节脂肪毒性,从而抑制纤维化。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-06 DOI: 10.1007/s42000-024-00612-4
Wen-Rui Li, Chunping Zhang, Jing Wang

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family of ligand-activated receptors and are known for their roles as key factors in the regulation of lipid metabolism. In the more than three decades since their discovery, most reports on PPARs have focused on their roles in lipid metabolism, and a portion of the new research has also focused on the relationship between PPARs and fibrosis. Interestingly, lipid metabolism disorders and fibrosis are also inextricably linked. This implies that PPARs, lipid metabolism and fibrosis are interrelated. On this basis, we have summarized the molecular mechanisms of PPARs regulating fibrosis through lipid metabolism and PPARγ directly regulating fibrosis, and pointed out the contradictions and enigmas that need to be further explored in the processes of PPARs regulating lipid metabolism and fibrosis. The aim of the present review is to provide new ideas for PPARs for the treatment of lipid metabolism disorders and fibrosis.

过氧化物酶体增殖激活受体(PPARs)属于配体激活受体的核荷尔蒙受体家族,是众所周知的调节脂质代谢的关键因素。自 PPARs 被发现以来的三十多年中,大多数有关 PPARs 的报道都集中于它们在脂质代谢中的作用,一部分新的研究也集中于 PPARs 与纤维化之间的关系。有趣的是,脂质代谢紊乱和纤维化之间也有着千丝万缕的联系。这意味着 PPARs、脂质代谢和纤维化是相互关联的。在此基础上,我们总结了PPARs通过脂质代谢调控纤维化和PPARγ直接调控纤维化的分子机制,并指出了PPARs调控脂质代谢和纤维化过程中需要进一步探讨的矛盾和谜团。本综述旨在为 PPARs 治疗脂质代谢紊乱和纤维化提供新思路。
{"title":"PPARs: modulating lipotoxicity and thus inhibiting fibrosis.","authors":"Wen-Rui Li, Chunping Zhang, Jing Wang","doi":"10.1007/s42000-024-00612-4","DOIUrl":"https://doi.org/10.1007/s42000-024-00612-4","url":null,"abstract":"<p><p>Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family of ligand-activated receptors and are known for their roles as key factors in the regulation of lipid metabolism. In the more than three decades since their discovery, most reports on PPARs have focused on their roles in lipid metabolism, and a portion of the new research has also focused on the relationship between PPARs and fibrosis. Interestingly, lipid metabolism disorders and fibrosis are also inextricably linked. This implies that PPARs, lipid metabolism and fibrosis are interrelated. On this basis, we have summarized the molecular mechanisms of PPARs regulating fibrosis through lipid metabolism and PPARγ directly regulating fibrosis, and pointed out the contradictions and enigmas that need to be further explored in the processes of PPARs regulating lipid metabolism and fibrosis. The aim of the present review is to provide new ideas for PPARs for the treatment of lipid metabolism disorders and fibrosis.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effects of exercise on anxiety symptoms in women with gestational diabetes mellitus: a pilot study. 运动对妊娠糖尿病妇女焦虑症状的影响:一项试点研究。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-11-06 DOI: 10.1007/s42000-024-00605-3
Eleftheria Taousani, Dimitra Savvaki, Maria G Grammatikopoulou, Gesthimani Mintziori, Anatoli Theodoridou, Zoi Koukou, Dimitrios G Goulis

Purpose: Anxiety is a common mental health issue during pregnancy. Moreover, women with gestational diabetes mellitus (GDM) seem to have to cope with higher levels of anxiety, being at higher risk for several health and mental complications. Women with GDM are recommended to undertake regular physical exercise to improve metabolic and reproductive outcomes. However, there are no specific guidelines for exercise in women with GDM and data on its relationship with mental health are scarce. The aim of this study was to investigate the effect of exercise on anxiety symptoms in pregnant women with GDM.

Methods: The present non-randomized, open-label clinical trial was a pilot study intended to provide initial data on the effect of exercise on anxiety symptoms of pregnant women with GDM. Forty-three women were assigned to three the following three study groups, (a) Advice Group (n = 17), Walking Group (n = 14), and Mixed Exercise Group (n = 12), from GDM diagnosis to delivery.

Results: Based on the Beck Anxiety Inventory (BAI) scores, all groups showed normal anxiety changes or mild anxiety levels pre- and post-intervention, ranging between 9.00 (1.00-32.00) (pre-intervention) and 7.5 (1.00-26.00) (post-intervention), but none experienced severe anxiety.

Conclusion: In the present study, a trend of self-selected pace walking to reduce the BAI scores was identified since the Walking Groups had lower scores after the intervention. However, this trend did not reach statistical significance. Brisk walking (30-45 min) three times per week may produce positive changes in both the treatment plan and the anxiety state of women with GDM. Moreover, the study confirms that routine medical care, counseling, and support by an interdisciplinary team are protective against anxiety in women with GDM.

目的:焦虑是孕期常见的心理健康问题。此外,患有妊娠糖尿病(GDM)的妇女似乎需要应对更高水平的焦虑,她们患上多种健康和精神并发症的风险也更高。建议患有 GDM 的妇女定期进行体育锻炼,以改善新陈代谢和生育能力。然而,目前还没有针对 GDM 妇女运动的具体指南,有关运动与心理健康关系的数据也很少。本研究旨在探讨运动对 GDM 孕妇焦虑症状的影响:本研究是一项非随机、开放标签临床试验,旨在提供运动对 GDM 孕妇焦虑症状影响的初步数据。从确诊为 GDM 到分娩,43 名孕妇被分配到以下三个研究组:(a)咨询组(17 人)、步行组(14 人)和混合运动组(12 人):根据贝克焦虑量表(BAI)评分,所有组别在干预前后均表现出正常焦虑变化或轻度焦虑水平,介于 9.00(1.00-32.00)(干预前)和 7.5(1.00-26.00)(干预后)之间,但无一出现严重焦虑:在本研究中,由于干预后步行组的得分较低,因此发现了自主选择步速步行可降低 BAI 分数的趋势。然而,这一趋势并没有达到统计学意义。每周三次的快走(30-45 分钟)可能会对 GDM 妇女的治疗计划和焦虑状态产生积极的影响。此外,该研究还证实,常规医疗护理、咨询和跨学科团队的支持对 GDM 妇女的焦虑具有保护作用。
{"title":"The effects of exercise on anxiety symptoms in women with gestational diabetes mellitus: a pilot study.","authors":"Eleftheria Taousani, Dimitra Savvaki, Maria G Grammatikopoulou, Gesthimani Mintziori, Anatoli Theodoridou, Zoi Koukou, Dimitrios G Goulis","doi":"10.1007/s42000-024-00605-3","DOIUrl":"https://doi.org/10.1007/s42000-024-00605-3","url":null,"abstract":"<p><strong>Purpose: </strong>Anxiety is a common mental health issue during pregnancy. Moreover, women with gestational diabetes mellitus (GDM) seem to have to cope with higher levels of anxiety, being at higher risk for several health and mental complications. Women with GDM are recommended to undertake regular physical exercise to improve metabolic and reproductive outcomes. However, there are no specific guidelines for exercise in women with GDM and data on its relationship with mental health are scarce. The aim of this study was to investigate the effect of exercise on anxiety symptoms in pregnant women with GDM.</p><p><strong>Methods: </strong>The present non-randomized, open-label clinical trial was a pilot study intended to provide initial data on the effect of exercise on anxiety symptoms of pregnant women with GDM. Forty-three women were assigned to three the following three study groups, (a) Advice Group (n = 17), Walking Group (n = 14), and Mixed Exercise Group (n = 12), from GDM diagnosis to delivery.</p><p><strong>Results: </strong>Based on the Beck Anxiety Inventory (BAI) scores, all groups showed normal anxiety changes or mild anxiety levels pre- and post-intervention, ranging between 9.00 (1.00-32.00) (pre-intervention) and 7.5 (1.00-26.00) (post-intervention), but none experienced severe anxiety.</p><p><strong>Conclusion: </strong>In the present study, a trend of self-selected pace walking to reduce the BAI scores was identified since the Walking Groups had lower scores after the intervention. However, this trend did not reach statistical significance. Brisk walking (30-45 min) three times per week may produce positive changes in both the treatment plan and the anxiety state of women with GDM. Moreover, the study confirms that routine medical care, counseling, and support by an interdisciplinary team are protective against anxiety in women with GDM.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 43-year-old man with hematometra: case report and literature review. 一名 43 岁男子的血子宫:病例报告和文献综述。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-31 DOI: 10.1007/s42000-024-00610-6
Elham Askary, Fatemeh Fakharmoghadam, Amirreza Dehghanian, Iman Shamohammad, Saeed Alborzi, Tahereh Poordast, Samaneh Mahmoodi, Shaghayegh Moradi Alamdarloo

In this case report, we present a 43-year-old man (XY) with azoospermia and typical male appearance, at Tanner stage 5 of sexual development, who presented with severe colicky abdominal pain accompanied by nausea. A pelvic CT scan revealed a pear-shaped structure in the pelvic cavity, located entirely behind the bladder, measuring 106*44 cm with fluid accumulation inside it, extending into the right inguinal canal. There was also evidence suggesting the formation of the upper and mid-third part of a vagina, terminating in the prostatic gland. The patient underwent laparoscopic surgery for the removal of the uterus and the left gonad. The patient had a uterus with hematometra and a blind vaginal pouch measuring 4 centimeters at the end of the uterus, extending posteriorly behind the bladder to the apex of the prostate, containing old blood. Hormonal analysis showed serum estradiol < 5.0 pmol/L (11-44pg/mL), free testosterone at 1.57 ng/ mL(male reference range: 2.5-20 ng/mL), testosterone at 0.56 ng/mL (2.27-10.30),FSH at 44.8 mIU/L (0.95-11.95 mIU/L), LH at 20.4 mIU/L(0.57-12.07), and DHEA-SO4 at 199.0 µg/mL (139.7-484.4 µg/mL). Currently, the patient is under the care of a urologist and is receiving weekly treatment with hCG medication. He reports normal sexual function, including intercourse, orgasm, erection, and ejaculation.

在本病例报告中,我们介绍了一名 43 岁的男性(XY),无精子症患者,典型的男性外貌,处于性发育的 Tanner 第 5 阶段。盆腔 CT 扫描显示,盆腔内有一个梨形结构,完全位于膀胱后方,大小为 106*44 厘米,内有积液,并延伸至右侧腹股沟管。还有证据表明,阴道的上半部和中段已经形成,末端是前列腺。患者接受了腹腔镜手术,切除了子宫和左侧性腺。患者的子宫有血肿,子宫末端有一个 4 厘米长的阴道盲袋,从膀胱后方一直延伸到前列腺顶端,内含陈旧性血液。激素分析显示血清雌二醇
{"title":"A 43-year-old man with hematometra: case report and literature review.","authors":"Elham Askary, Fatemeh Fakharmoghadam, Amirreza Dehghanian, Iman Shamohammad, Saeed Alborzi, Tahereh Poordast, Samaneh Mahmoodi, Shaghayegh Moradi Alamdarloo","doi":"10.1007/s42000-024-00610-6","DOIUrl":"https://doi.org/10.1007/s42000-024-00610-6","url":null,"abstract":"<p><p>In this case report, we present a 43-year-old man (XY) with azoospermia and typical male appearance, at Tanner stage 5 of sexual development, who presented with severe colicky abdominal pain accompanied by nausea. A pelvic CT scan revealed a pear-shaped structure in the pelvic cavity, located entirely behind the bladder, measuring 106*44 cm with fluid accumulation inside it, extending into the right inguinal canal. There was also evidence suggesting the formation of the upper and mid-third part of a vagina, terminating in the prostatic gland. The patient underwent laparoscopic surgery for the removal of the uterus and the left gonad. The patient had a uterus with hematometra and a blind vaginal pouch measuring 4 centimeters at the end of the uterus, extending posteriorly behind the bladder to the apex of the prostate, containing old blood. Hormonal analysis showed serum estradiol < 5.0 pmol/L (11-44pg/mL), free testosterone at 1.57 ng/ mL(male reference range: 2.5-20 ng/mL), testosterone at 0.56 ng/mL (2.27-10.30),FSH at 44.8 mIU/L (0.95-11.95 mIU/L), LH at 20.4 mIU/L(0.57-12.07), and DHEA-SO4 at 199.0 µg/mL (139.7-484.4 µg/mL). Currently, the patient is under the care of a urologist and is receiving weekly treatment with hCG medication. He reports normal sexual function, including intercourse, orgasm, erection, and ejaculation.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of anti-Müllerian hormone in female children and adolescents. 抗缪勒氏管激素在女性儿童和青少年中的临床应用。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-31 DOI: 10.1007/s42000-024-00603-5
Effrosyni Birbas, Anastasia Vatopoulou, Theofilos Kanavos, Kyriakos Birmpas, Chara Skentou, Athanasios Zikopoulos, Fani Gkrozou

Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that belongs to the transforming growth factor beta superfamily and plays essential roles in sexual differentiation and folliculogenesis. In the male embryo, AMH is produced by the Sertoli cells and induces the involution of the Müllerian ducts. In females, AMH is predominately produced by the granulosa cells of growing preantral and small antral follicles and regulates follicular maturation. Many recent studies have highlighted the significant role of this hormone in the diagnostic approach to female children and adolescents with various disorders that affect ovarian development and function. AMH is considered a valuable diagnostic tool in the management of female pediatric patients with conditions such as polycystic ovary syndrome, precocious puberty, ovarian tumors, differences in sex development, and premature ovarian insufficiency. Standardization of AMH assays, internationally approved reference values based on age and pubertal stage, and widespread availability of the test could further upgrade the clinical utility of AMH, rendering it a valuable tool in the armamentarium of physicians involved in the care of female children and adolescents, and promote future research.

抗缪勒氏管激素(AMH)是一种二聚糖蛋白,属于转化生长因子β超家族,在性分化和卵泡生成过程中发挥着重要作用。在雄性胚胎中,AMH 由 Sertoli 细胞产生,诱导 Müllerian 管内陷。在雌性胚胎中,AMH主要由生长中的前前卵泡和小前卵泡的颗粒细胞产生,并调节卵泡的成熟。最近的许多研究都强调了这种激素在诊断患有影响卵巢发育和功能的各种疾病的女性儿童和青少年中的重要作用。AMH 被认为是治疗患有多囊卵巢综合症、性早熟、卵巢肿瘤、性发育差异和卵巢早衰等疾病的女性儿科患者的重要诊断工具。AMH检测方法的标准化、基于年龄和青春期阶段的国际认可参考值以及该检测方法的普及可进一步提高AMH的临床实用性,使其成为从事女性儿童和青少年护理的医生的重要工具,并促进未来的研究。
{"title":"Clinical utility of anti-Müllerian hormone in female children and adolescents.","authors":"Effrosyni Birbas, Anastasia Vatopoulou, Theofilos Kanavos, Kyriakos Birmpas, Chara Skentou, Athanasios Zikopoulos, Fani Gkrozou","doi":"10.1007/s42000-024-00603-5","DOIUrl":"https://doi.org/10.1007/s42000-024-00603-5","url":null,"abstract":"<p><p>Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that belongs to the transforming growth factor beta superfamily and plays essential roles in sexual differentiation and folliculogenesis. In the male embryo, AMH is produced by the Sertoli cells and induces the involution of the Müllerian ducts. In females, AMH is predominately produced by the granulosa cells of growing preantral and small antral follicles and regulates follicular maturation. Many recent studies have highlighted the significant role of this hormone in the diagnostic approach to female children and adolescents with various disorders that affect ovarian development and function. AMH is considered a valuable diagnostic tool in the management of female pediatric patients with conditions such as polycystic ovary syndrome, precocious puberty, ovarian tumors, differences in sex development, and premature ovarian insufficiency. Standardization of AMH assays, internationally approved reference values based on age and pubertal stage, and widespread availability of the test could further upgrade the clinical utility of AMH, rendering it a valuable tool in the armamentarium of physicians involved in the care of female children and adolescents, and promote future research.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can a mobile application improve glucose-related and patient-reported outcome measures (PROMs) in people with type 1 diabetes mellitus? A randomized controlled trial using the mySugr® app. 移动应用程序能否改善 1 型糖尿病患者的血糖相关指标和患者报告结果(PROMs)?使用 mySugr® 应用程序的随机对照试验。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-16 DOI: 10.1007/s42000-024-00609-z
Gemma Cuixart, Rosa Corcoy, Cintia González

Purpose: Mobile applications (apps) have proven to be highly effective tools to empower patients with type 1 diabetes mellitus (T1DM) and enable them to achieve better self-care, quality of life (QOL), and glycemic control. The aim of the study is to examine whether mySugr®, an app for diabetes management, together with teleconsultations, can have a positive impact on these factors and, thereby, replace current clinical care.

Methods: This study concerns an exploratory randomized clinical trial of 12 months' duration. People with T1DM using multiple daily injections were randomized to usual care (bolus calculator, five face-to-face visits) or intervention (mySugr® app, three face-to-face visits, and two teleconsultations). The main outcome was increase in empowerment assessed with the Diabetes Empowerment Scale Short Form questionnaire (DES-SF-S). Secondary outcomes were change in additional glucose-related (blood glucose monitoring, mean blood glucose, standard deviation, coefficient of variation (CV), and high and low blood glucose index) and patient-reported outcome measures (PROMs) (self-management, QOL, and distress).

Results: A total of 25 out of 28 participants completed the study (52% men, age 44.52 years, diabetes duration 21.28 years). At 12 months, no significant differences were identified in the change of DES-SF-S and additional PROMs between arms. Similarly, no differences were observed in glucose-related outcomes except for the change in CV at 9 (control - 1.87 ± 4.98 vs. intervention 5.89 ± 11.33, p = 0.008) and 12 months (control - 2.33 ± 3.54 vs. intervention 5.12 ± 11.32, p = 0.018). Adherence to and satisfaction with the app were high.

Conclusion: Patients with diabetes using the mySugr® app and teleconsultation achieved similar results to those following usual care in empowerment, other PROMs, and most glucose-related outcomes, thus supporting its use in combination with face-to-face visits. The RCT was registered with ClinicalTrials.gov (NCT03819335, first registration 28/01/2019).

目的:事实证明,移动应用程序(App)是增强 1 型糖尿病(T1DM)患者能力的高效工具,可使他们获得更好的自我护理、生活质量(QOL)和血糖控制。本研究旨在探讨用于糖尿病管理的应用程序 mySugr® 与远程会诊相结合是否能对这些因素产生积极影响,从而取代目前的临床治疗:本研究是一项为期 12 个月的探索性随机临床试验。每日多次注射的 T1DM 患者被随机分配到常规治疗(药量计算器、五次面诊)或干预治疗(mySugr® 应用程序、三次面诊和两次远程会诊)。主要结果是通过糖尿病赋权量表简表问卷(DES-SF-S)评估赋权的增加情况。次要结果是其他血糖相关指标(血糖监测、平均血糖、标准偏差、变异系数(CV)、高血糖指数和低血糖指数)和患者报告结果指标(PROMs)(自我管理、生活质量和痛苦)的变化:28 名参与者中共有 25 人完成了研究(52% 为男性,年龄 44.52 岁,糖尿病病程 21.28 年)。12个月后,各组间的DES-SF-S和其他PROM指标变化无明显差异。同样,除了 9 个月和 12 个月的 CV 变化(对照组 - 1.87 ± 4.98 vs. 干预组 5.89 ± 11.33,p = 0.008)和 12 个月的 CV 变化(对照组 - 2.33 ± 3.54 vs. 干预组 5.12 ± 11.32,p = 0.018)外,在血糖相关结果方面也未观察到差异。应用的坚持率和满意度都很高:结论:使用 mySugr® 应用程序和远程会诊的糖尿病患者在增强能力、其他 PROMs 和大多数血糖相关结果方面与接受常规护理的患者取得了相似的结果,因此支持将其与面对面会诊结合使用。该研究已在 ClinicalTrials.gov 注册(NCT03819335,首次注册日期为 2019 年 1 月 28 日)。
{"title":"Can a mobile application improve glucose-related and patient-reported outcome measures (PROMs) in people with type 1 diabetes mellitus? A randomized controlled trial using the mySugr<sup>®</sup> app.","authors":"Gemma Cuixart, Rosa Corcoy, Cintia González","doi":"10.1007/s42000-024-00609-z","DOIUrl":"https://doi.org/10.1007/s42000-024-00609-z","url":null,"abstract":"<p><strong>Purpose: </strong>Mobile applications (apps) have proven to be highly effective tools to empower patients with type 1 diabetes mellitus (T1DM) and enable them to achieve better self-care, quality of life (QOL), and glycemic control. The aim of the study is to examine whether mySugr<sup>®</sup>, an app for diabetes management, together with teleconsultations, can have a positive impact on these factors and, thereby, replace current clinical care.</p><p><strong>Methods: </strong>This study concerns an exploratory randomized clinical trial of 12 months' duration. People with T1DM using multiple daily injections were randomized to usual care (bolus calculator, five face-to-face visits) or intervention (mySugr<sup>®</sup> app, three face-to-face visits, and two teleconsultations). The main outcome was increase in empowerment assessed with the Diabetes Empowerment Scale Short Form questionnaire (DES-SF-S). Secondary outcomes were change in additional glucose-related (blood glucose monitoring, mean blood glucose, standard deviation, coefficient of variation (CV), and high and low blood glucose index) and patient-reported outcome measures (PROMs) (self-management, QOL, and distress).</p><p><strong>Results: </strong>A total of 25 out of 28 participants completed the study (52% men, age 44.52 years, diabetes duration 21.28 years). At 12 months, no significant differences were identified in the change of DES-SF-S and additional PROMs between arms. Similarly, no differences were observed in glucose-related outcomes except for the change in CV at 9 (control - 1.87 ± 4.98 vs. intervention 5.89 ± 11.33, p = 0.008) and 12 months (control - 2.33 ± 3.54 vs. intervention 5.12 ± 11.32, p = 0.018). Adherence to and satisfaction with the app were high.</p><p><strong>Conclusion: </strong>Patients with diabetes using the mySugr<sup>®</sup> app and teleconsultation achieved similar results to those following usual care in empowerment, other PROMs, and most glucose-related outcomes, thus supporting its use in combination with face-to-face visits. The RCT was registered with ClinicalTrials.gov (NCT03819335, first registration 28/01/2019).</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity and overweight are common among hospitalized patients and are associated with specific causes of admission to an internal medicine department: a cross-sectional study. 肥胖和超重在住院病人中很常见,并与内科住院的特定原因有关:一项横断面研究。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-11 DOI: 10.1007/s42000-024-00611-5
Frideriki Karanikola, Nikolaos Devrikis, Djordje S Popovic, Dimitrios Patoulias, Kalliopi Kotsa, Michael Doumas, Theocharis Koufakis

Purpose: Data on the prevalence of obesity among hospitalized patients are limited. Our objective was to capture the rates of overweight and obesity among people admitted to an internal medicine department and to explore a potential association between body mass index (BMI) and causes of hospitalization.

Methods: Demographic and anthropometric parameters and cause of admission were recorded in all patients admitted to our department over a 30-day period.

Results: One hundred and eighteen patients with a mean age of 71.84 years and a mean BMI of 26.85 kg/m2 were included in the analysis. Among study participants, 53.25% were living with overweight and obesity. Patients admitted for hepatobiliary disease had a higher BMI compared to those admitted for other diseases of the gastrointestinal tract (P < 0.001).

Conclusions: More than half of patients admitted to an internal medicine department live with obesity or overweight, the specific reasons for admission being associated with a higher BMI.

目的:有关住院病人肥胖患病率的数据十分有限。我们的目的是了解内科住院病人的超重和肥胖率,并探讨体重指数(BMI)与住院原因之间的潜在联系:方法:记录我科所有住院病人在 30 天内的人口统计学、人体测量参数和入院原因:分析对象包括 118 名患者,平均年龄为 71.84 岁,平均体重指数为 26.85 kg/m2。研究参与者中,53.25%为超重和肥胖患者。因肝胆疾病入院的患者的体重指数高于因其他胃肠道疾病入院的患者(P结论):在内科住院的患者中,半数以上患有肥胖症或超重症,入院的具体原因与较高的体重指数有关。
{"title":"Obesity and overweight are common among hospitalized patients and are associated with specific causes of admission to an internal medicine department: a cross-sectional study.","authors":"Frideriki Karanikola, Nikolaos Devrikis, Djordje S Popovic, Dimitrios Patoulias, Kalliopi Kotsa, Michael Doumas, Theocharis Koufakis","doi":"10.1007/s42000-024-00611-5","DOIUrl":"https://doi.org/10.1007/s42000-024-00611-5","url":null,"abstract":"<p><strong>Purpose: </strong>Data on the prevalence of obesity among hospitalized patients are limited. Our objective was to capture the rates of overweight and obesity among people admitted to an internal medicine department and to explore a potential association between body mass index (BMI) and causes of hospitalization.</p><p><strong>Methods: </strong>Demographic and anthropometric parameters and cause of admission were recorded in all patients admitted to our department over a 30-day period.</p><p><strong>Results: </strong>One hundred and eighteen patients with a mean age of 71.84 years and a mean BMI of 26.85 kg/m<sup>2</sup> were included in the analysis. Among study participants, 53.25% were living with overweight and obesity. Patients admitted for hepatobiliary disease had a higher BMI compared to those admitted for other diseases of the gastrointestinal tract (P < 0.001).</p><p><strong>Conclusions: </strong>More than half of patients admitted to an internal medicine department live with obesity or overweight, the specific reasons for admission being associated with a higher BMI.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silencing LncRNA SNHG14 alleviates renal tubular injury via the miR-483-5p/HDAC4 axis in diabetic kidney disease. 沉默LncRNA SNHG14可通过miR-483-5p/HDAC4轴减轻糖尿病肾病的肾小管损伤
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-08 DOI: 10.1007/s42000-024-00606-2
Qiwu Huang, Tianyi Qiu, Huanzhen Chen, Tongguan Tian, Dan Wang, Chang Lu

Purpose: This study explored the clinical value of long non-coding RNA small nucleolar RNA host gene 14 (SNHG14) in diabetic kidney disease (DKD) and the mechanism of renal tubular injury.

Methods: Patients with DKD, type 2 diabetes mellitus (T2DM) and healthy individuals (HVs) were included, as well as the human proximal tubular epithelial cell line (HK-2) induced by high glucose was also included. The mRNA levels of SNHG14 in the serum and cells were detected using RT-qPCR. Diagnostic significance was examined using receiver operating characteristic (ROC) analysis. A commercial test kit, flow cytometry, and enzyme-linked immunosorbent assays were employed to assess reactive oxygen species (ROS) production, apoptosis, inflammatory factor secretion, and extracellular matrix protein levels in HK-2 cells. The dual-luciferase reporter assay and RNA immunoprecipitation were used to validate miR-483-5p concerning SNHG14 or histone deacetylase 4 (HDAC4).

Results: SNHG14 and HDAC4 levels were elevated in the serum of DKD patients and HG-induced HK-2 cells, while miR-483-5p levels were decreased (P < 0.001). SNHG14 increased HDAC4 levels by sponging miR-483-5p. Elevated SNHG14 levels significantly differentiated DKD patients from HVs (AUC = 0.944) and T2DM (AUC = 0.867). Silencing of SNHG14 alleviated HG-induced ROS production and apoptosis as well as the over-secretion of inflammatory factors and extracellular matrix proteins; however, this alleviation was typically suppressed by low expression of miR-483-5p (P < 0.001). Elevated miR-483-5p alleviates HG-induced renal tubular injury, but this alleviation is suppressed by HDAC4 overexpression.

Conclusion: In summary, suppression of SNHG14 has been shown in our study to mitigate renal tubular injury in DKD by regulating apoptosis, oxidative stress, inflammation, and fibrosis through the miR-483-5p/HDAC4 axis.

目的:本研究探讨了长非编码RNA小核仁RNA宿主基因14(SNHG14)在糖尿病肾病(DKD)中的临床价值以及肾小管损伤的机制:方法:研究对象包括糖尿病肾病(DKD)患者、2型糖尿病(T2DM)患者和健康人(HVs),以及由高糖诱导的人近曲小管上皮细胞系(HK-2)。采用 RT-qPCR 检测血清和细胞中 SNHG14 的 mRNA 水平。诊断意义采用接收器操作特征(ROC)分析法进行检验。采用商业检测试剂盒、流式细胞术和酶联免疫吸附试验来评估 HK-2 细胞中活性氧(ROS)的产生、细胞凋亡、炎症因子分泌和细胞外基质蛋白水平。双荧光素酶报告试验和 RNA 免疫共沉淀被用来验证 miR-483-5p 与 SNHG14 或组蛋白去乙酰化酶 4 (HDAC4) 的关系:结果:在DKD患者血清和HG诱导的HK-2细胞中,SNHG14和HDAC4的水平升高,而miR-483-5p的水平下降(P总之,我们的研究表明,抑制 SNHG14 可通过 miR-483-5p/HDAC4 轴调节细胞凋亡、氧化应激、炎症和纤维化,从而减轻 DKD 肾小管损伤。
{"title":"Silencing LncRNA SNHG14 alleviates renal tubular injury via the miR-483-5p/HDAC4 axis in diabetic kidney disease.","authors":"Qiwu Huang, Tianyi Qiu, Huanzhen Chen, Tongguan Tian, Dan Wang, Chang Lu","doi":"10.1007/s42000-024-00606-2","DOIUrl":"https://doi.org/10.1007/s42000-024-00606-2","url":null,"abstract":"<p><strong>Purpose: </strong>This study explored the clinical value of long non-coding RNA small nucleolar RNA host gene 14 (SNHG14) in diabetic kidney disease (DKD) and the mechanism of renal tubular injury.</p><p><strong>Methods: </strong>Patients with DKD, type 2 diabetes mellitus (T2DM) and healthy individuals (HVs) were included, as well as the human proximal tubular epithelial cell line (HK-2) induced by high glucose was also included. The mRNA levels of SNHG14 in the serum and cells were detected using RT-qPCR. Diagnostic significance was examined using receiver operating characteristic (ROC) analysis. A commercial test kit, flow cytometry, and enzyme-linked immunosorbent assays were employed to assess reactive oxygen species (ROS) production, apoptosis, inflammatory factor secretion, and extracellular matrix protein levels in HK-2 cells. The dual-luciferase reporter assay and RNA immunoprecipitation were used to validate miR-483-5p concerning SNHG14 or histone deacetylase 4 (HDAC4).</p><p><strong>Results: </strong>SNHG14 and HDAC4 levels were elevated in the serum of DKD patients and HG-induced HK-2 cells, while miR-483-5p levels were decreased (P < 0.001). SNHG14 increased HDAC4 levels by sponging miR-483-5p. Elevated SNHG14 levels significantly differentiated DKD patients from HVs (AUC = 0.944) and T2DM (AUC = 0.867). Silencing of SNHG14 alleviated HG-induced ROS production and apoptosis as well as the over-secretion of inflammatory factors and extracellular matrix proteins; however, this alleviation was typically suppressed by low expression of miR-483-5p (P < 0.001). Elevated miR-483-5p alleviates HG-induced renal tubular injury, but this alleviation is suppressed by HDAC4 overexpression.</p><p><strong>Conclusion: </strong>In summary, suppression of SNHG14 has been shown in our study to mitigate renal tubular injury in DKD by regulating apoptosis, oxidative stress, inflammation, and fibrosis through the miR-483-5p/HDAC4 axis.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing the benefits of physical exercise-induced melatonin: a potential promising approach to combat Alzheimer's disease by targeting beta-amyloid (Aβ). 利用体育锻炼诱导褪黑激素的益处:通过靶向β-淀粉样蛋白(Aβ)防治阿尔茨海默氏症的潜在可行方法。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-23 DOI: 10.1007/s42000-024-00602-6
Rui Bian, Lijuan Xiang, Zhang Su

Alzheimer's disease (AD) is a chronic neurogenerative disease that impairs cognition, learning, behavior, and memory. The aberrant accumulation of extracellular amyloid-β (Aβ) plaques is a characteristic of AD. It has been demonstrated that melatonin exerts a significant role in AD prevention and treatment via its antioxidant effects, reducing neuroinflammation, and Aβ. Moreover, studies have shown that physical exercise (PE) is not only a promising non-pharmacological strategy for AD prevention and treatment but can also lead to an increase in melatonin levels. Hence, we hypothesized that PE can contribute to AD prevention and treatment by increasing melatonin levels and reducing Aβ accumulation, enhancing Aβ clearance, and modulating inflammation in these patients. However, the mechanisms by which PE increases melatonin synthesis and the cellular and molecular mechanisms of actions of melatonin in AD prevention and treatment have not to date been completely understood. Therefore, in the future, further investigations are required to elucidate the underlying mechanisms, optimize intervention strategies, identify biomarkers, and validate findings through clinical trials. Understanding the potential of exercise-induced melatonin in AD holds promise for innovative therapeutic interventions and future directions in AD research.

阿尔茨海默病(AD)是一种慢性神经退行性疾病,会损害认知、学习、行为和记忆。细胞外淀粉样蛋白-β(Aβ)斑块的异常积累是阿尔茨海默病的特征之一。研究表明,褪黑激素通过其抗氧化作用、减少神经炎症和 Aβ,在预防和治疗老年痴呆症方面发挥着重要作用。此外,有研究表明,体育锻炼(PE)不仅是一种很有前景的预防和治疗AD的非药物策略,而且还能提高褪黑激素水平。因此,我们推测体育锻炼可以通过提高褪黑激素水平、减少Aβ的积累、提高Aβ的清除率以及调节炎症反应来预防和治疗AD。然而,PE增加褪黑激素合成的机制以及褪黑激素在AD预防和治疗中的细胞和分子作用机制至今尚未完全清楚。因此,未来还需要进一步的研究来阐明其潜在机制,优化干预策略,确定生物标志物,并通过临床试验来验证研究结果。了解运动诱导褪黑激素在老年痴呆症中的潜在作用有望为创新性治疗干预措施和老年痴呆症研究的未来方向带来希望。
{"title":"Harnessing the benefits of physical exercise-induced melatonin: a potential promising approach to combat Alzheimer's disease by targeting beta-amyloid (Aβ).","authors":"Rui Bian, Lijuan Xiang, Zhang Su","doi":"10.1007/s42000-024-00602-6","DOIUrl":"https://doi.org/10.1007/s42000-024-00602-6","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a chronic neurogenerative disease that impairs cognition, learning, behavior, and memory. The aberrant accumulation of extracellular amyloid-β (Aβ) plaques is a characteristic of AD. It has been demonstrated that melatonin exerts a significant role in AD prevention and treatment via its antioxidant effects, reducing neuroinflammation, and Aβ. Moreover, studies have shown that physical exercise (PE) is not only a promising non-pharmacological strategy for AD prevention and treatment but can also lead to an increase in melatonin levels. Hence, we hypothesized that PE can contribute to AD prevention and treatment by increasing melatonin levels and reducing Aβ accumulation, enhancing Aβ clearance, and modulating inflammation in these patients. However, the mechanisms by which PE increases melatonin synthesis and the cellular and molecular mechanisms of actions of melatonin in AD prevention and treatment have not to date been completely understood. Therefore, in the future, further investigations are required to elucidate the underlying mechanisms, optimize intervention strategies, identify biomarkers, and validate findings through clinical trials. Understanding the potential of exercise-induced melatonin in AD holds promise for innovative therapeutic interventions and future directions in AD research.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical application of cluster analysis in patients with newly diagnosed type 2 diabetes. 聚类分析在新诊断 2 型糖尿病患者中的临床应用。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-04 DOI: 10.1007/s42000-024-00593-4
Yazhi Wang, Hui Chen
<p><strong>Aims: </strong>Early prevention and treatment of type 2 diabetes mellitus (T2DM) is still a huge challenge for patients and clinicians. Recently, a novel cluster-based diabetes classification was proposed which may offer the possibility to solve this problem. In this study, we report our performance of cluster analysis of individuals newly diagnosed with T2DM, our exploration of each subtype's clinical characteristics and medication treatment, and the comparison carried out concerning the risk for diabetes complications and comorbidities among subtypes by adjusting for influencing factors. We hope to promote the further application of cluster analysis in individuals with early-stage T2DM.</p><p><strong>Methods: </strong>In this study, a k-means cluster algorithm was applied based on five indicators, namely, age, body mass index (BMI), glycosylated hemoglobin (HbA1c), homeostasis model assessment-2 insulin resistance (HOMA2-IR), and homeostasis model assessment-2 β-cell function (HOMA2-β), in order to perform the cluster analysis among 567 newly diagnosed participants with T2DM. The clinical characteristics and medication of each subtype were analyzed. The risk for diabetes complications and comorbidities in each subtype was compared by logistic regression analysis.</p><p><strong>Results: </strong>The 567 patients were clustered into four subtypes, as follows: severe insulin-deficient diabetes (SIDD, 24.46%), age-related diabetes (MARD, 30.86%), mild obesity-related diabetes (MOD, 25.57%), and severe insulin-resistant diabetes (SIRD, 20.11%). According to the results of the oral glucose tolerance test (OGTT) and biochemical indices, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hBG), HbA1c, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride-glucose index (TyG) were higher in SIDD and SIRD than in MARD and MOD. MOD had the highest fasting C-peptide (FCP), 2-hour postprandial C-peptide (2hCP), fasting insulin (FINS), 2-hour postprandial insulin (2hINS), serum creatinine (SCr), and uric acid (UA), while SIRD had the highest triglycerides (TGs) and TyG-BMI. Albumin transaminase (ALT) and albumin transaminase (AST) were higher in MOD and SIRD. As concerms medications, compared to the other subtypes, SIDD had a lower rate of metformin use (39.1%) and a higher rate of α-glucosidase inhibitor (AGI, 61.7%) and insulin (74.4%) use. SIRD showed the highest frequency of use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i, 36.0%) and glucagon-like peptide-1 receptor agonists (GLP-1RA, 19.3%). Concerning diabetic complications and comorbidities, the prevalence of diabetic kidney disease (DKD), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and hypertension differed significantly among subtypes. Employing logistic regression analysis, after adjusting for unmodifiable (sex and age) and modifiable related influences (e.g., BMI, HbA1c, and smoking), it was
目的:对于患者和临床医生来说,早期预防和治疗 2 型糖尿病(T2DM)仍然是一个巨大的挑战。最近,一种新的基于聚类的糖尿病分类方法被提出,它为解决这一问题提供了可能。在本研究中,我们报告了对新诊断出的 T2DM 患者进行聚类分析的结果,探讨了各亚型的临床特征和药物治疗,并通过调整影响因素,比较了各亚型之间糖尿病并发症和合并症的风险。我们希望能促进聚类分析在早期 T2DM 患者中的进一步应用:本研究基于年龄、体重指数(BMI)、糖化血红蛋白(HbA1c)、稳态模型评估-2胰岛素抵抗(HOMA2-IR)和稳态模型评估-2β细胞功能(HOMA2-β)五项指标,采用k均值聚类算法对567名新诊断的T2DM患者进行聚类分析。分析了每个亚型的临床特征和用药情况。通过逻辑回归分析比较了各亚型的糖尿病并发症和合并症风险:结果:567 名患者被分为以下四个亚型:重度胰岛素缺乏性糖尿病(SIDD,24.46%)、年龄相关性糖尿病(MARD,30.86%)、轻度肥胖相关性糖尿病(MOD,25.57%)和重度胰岛素抵抗性糖尿病(SIRD,20.11%)。根据口服葡萄糖耐量试验(OGTT)结果和生化指标,SIDD 和 SIRD 的空腹血糖(FBG)、餐后 2 小时血糖(2hBG)、HbA1c、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯-葡萄糖指数(TyG)均高于 MARD 和 MOD。MOD 的空腹 C 肽(FCP)、餐后 2 小时 C 肽(2hCP)、空腹胰岛素(FINS)、餐后 2 小时胰岛素(2hINS)、血清肌酐(SCr)和尿酸(UA)最高,而 SIRD 的甘油三酯(TGs)和 TyG-BMI 最高。MOD 和 SIRD 的白蛋白转氨酶(ALT)和白蛋白转氨酶(AST)较高。在药物方面,与其他亚型相比,SIDD 使用二甲双胍的比例较低(39.1%),而使用α-葡萄糖苷酶抑制剂(AGI,61.7%)和胰岛素(74.4%)的比例较高。SIRD 使用钠-葡萄糖共转运体-2 抑制剂(SGLT-2i,36.0%)和胰高血糖素样肽-1 受体激动剂(GLP-1RA,19.3%)的频率最高。在糖尿病并发症和合并症方面,糖尿病肾病(DKD)、心血管疾病(CVD)、非酒精性脂肪肝(NAFLD)、血脂异常和高血压的患病率在不同亚型之间存在显著差异。采用逻辑回归分析,在调整了不可改变(性别和年龄)和可改变的相关影响因素(如体重指数、血红蛋白A1c和吸烟)后,发现SIRD患DKD(几率比,OR = 2.001,95%置信区间(CI):1.125-3.559)和血脂异常(OR = 3.550,95%置信区间(CI):1.534-8.215)的风险最高。MOD更有可能患有非酒精性脂肪肝(OR = 3.301,95%CI:1.586-6.870):结论:新诊断的T2DM患者可被成功聚类为四个亚型,这些亚型具有不同的临床特征、药物治疗、糖尿病相关并发症和合并症风险,基于聚类的糖尿病分类可能对预防继发性糖尿病和建立精准医疗的理论基础有益。
{"title":"Clinical application of cluster analysis in patients with newly diagnosed type 2 diabetes.","authors":"Yazhi Wang, Hui Chen","doi":"10.1007/s42000-024-00593-4","DOIUrl":"https://doi.org/10.1007/s42000-024-00593-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims: &lt;/strong&gt;Early prevention and treatment of type 2 diabetes mellitus (T2DM) is still a huge challenge for patients and clinicians. Recently, a novel cluster-based diabetes classification was proposed which may offer the possibility to solve this problem. In this study, we report our performance of cluster analysis of individuals newly diagnosed with T2DM, our exploration of each subtype's clinical characteristics and medication treatment, and the comparison carried out concerning the risk for diabetes complications and comorbidities among subtypes by adjusting for influencing factors. We hope to promote the further application of cluster analysis in individuals with early-stage T2DM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this study, a k-means cluster algorithm was applied based on five indicators, namely, age, body mass index (BMI), glycosylated hemoglobin (HbA1c), homeostasis model assessment-2 insulin resistance (HOMA2-IR), and homeostasis model assessment-2 β-cell function (HOMA2-β), in order to perform the cluster analysis among 567 newly diagnosed participants with T2DM. The clinical characteristics and medication of each subtype were analyzed. The risk for diabetes complications and comorbidities in each subtype was compared by logistic regression analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The 567 patients were clustered into four subtypes, as follows: severe insulin-deficient diabetes (SIDD, 24.46%), age-related diabetes (MARD, 30.86%), mild obesity-related diabetes (MOD, 25.57%), and severe insulin-resistant diabetes (SIRD, 20.11%). According to the results of the oral glucose tolerance test (OGTT) and biochemical indices, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hBG), HbA1c, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride-glucose index (TyG) were higher in SIDD and SIRD than in MARD and MOD. MOD had the highest fasting C-peptide (FCP), 2-hour postprandial C-peptide (2hCP), fasting insulin (FINS), 2-hour postprandial insulin (2hINS), serum creatinine (SCr), and uric acid (UA), while SIRD had the highest triglycerides (TGs) and TyG-BMI. Albumin transaminase (ALT) and albumin transaminase (AST) were higher in MOD and SIRD. As concerms medications, compared to the other subtypes, SIDD had a lower rate of metformin use (39.1%) and a higher rate of α-glucosidase inhibitor (AGI, 61.7%) and insulin (74.4%) use. SIRD showed the highest frequency of use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i, 36.0%) and glucagon-like peptide-1 receptor agonists (GLP-1RA, 19.3%). Concerning diabetic complications and comorbidities, the prevalence of diabetic kidney disease (DKD), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and hypertension differed significantly among subtypes. Employing logistic regression analysis, after adjusting for unmodifiable (sex and age) and modifiable related influences (e.g., BMI, HbA1c, and smoking), it was ","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hormones-International Journal of Endocrinology and Metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1